Результаты поиска

Patient-reported outcomes in cancer survivorship: insights from two decades of population-based PROFILES registry research.

PurposeWhen the field of cancer survivorship research was in its infancy, the PROFILES registry was set up in 2004 to monitor patient-reported outcomes (PROs) in survivors and a normative population. This scoping review aims to summarize lessons learned from developing a population-based PRO registry, focusing on study methodologies, data collection shifts, data utilization, multidisciplinary collaboration, societal impact, and data sharing.MethodsA systematic computerized literature search through PubMed was performed to collect all publications using data from the PROFILES registry between J

Совпадение в полном тексте источника
… Sangha O The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research Arthritis Rheum 2003 49 2 156 163 10.1002/art.10993 12687505 Sangha O, et al. … Arthritis Rheum. 2003;49(2):156–63. 12687505 10.1002/art.10993 97. Hinnen C, Mols F. Fluctuations in core depressive symptoms in colorectal cancer patients. a prospective, population-based PROFILES-registry study. …

Exploring COX-Independent Pathways: A Novel Approach for Meloxicam and Other NSAIDs in Cancer and Cardiovascular Disease Treatment.

As a fundamental process of innate immunity, inflammation is associated with the pathologic process of various diseases and constitutes a prevalent risk factor for both cancer and cardiovascular disease (CVD). Studies have indicated that several non-steroidal anti-inflammatory drugs (NSAIDs), including Meloxicam, may prevent tumorigenesis, reduce the risk of carcinogenesis, improve the efficacy of anticancer therapies, and reduce the risk of CVD, in addition to controlling the body's inflammatory imbalances. Traditionally, most NSAIDs work by inhibiting cyclooxygenase (COX) activity, thereby b

Совпадение в полном тексте источника
… Arthritis Rheum. 2008;58:1354–1365. doi: 10.1002/art.23453. 10. Howe L.R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9:210. doi: 10.1186/bcr1678. 11. … Arthritis Rheum. 1997;26((Suppl. S1)):21–27. doi: 10.1016/S0049-0172(97)80049-2. 15. Goldman A.P., Williams C.S., Sheng H., Lamps L.W., Williams V.P., Pairet M., Morrow J.D., DuBois R.N. Meloxicam inhibits the growth of colorectal cancer cells. …

Талидомид взаимодействует с воспалением в идиопатическом фиброзе легких.

" Трагедия Талидомида " является важной вехой в истории фармацевтической промышленности. Несмотря на ограниченные клинические испытания, прилагаются постоянные усилия по изучению Талидомида в качестве лекарства от рака и подстрекательских заболеваний, таких, как ревматуидный артрит, проказа, и COVID-19. В рамках этого обзора основное внимание уделяется возможностям борьбы с воспалением путем повторного использования талидомида для лечения идиопатического фиброза легких (ИПФ). Статьи были найдены в базе данных Scopus, сортированы и рассмотрены отдельные статьи. Содержание включает в с

Совпадение в аннотации оригинала
The "Thalidomide tragedy" is a landmark in the history of the pharmaceutical industry. Despite limited clinical trials, there is a continuous effort to investigate thalidomide as a drug for cancer and inflammatory diseases such as rheumatoid arthritis, lepromatous leprosy, and COVID-19. This review focuses on the possibilities of targeting inflammation by re…

The Risk of Sarcoidosis Misdiagnosis and the Harmful Effect of Corticosteroids When the Disease Picture Is Incomplete.

Sarcoidosis is a complex granulomatous disease of unknown etiology. Due to the heterogeneity of the disease, the diagnosis remains challenging in many cases, often at the physician's discretion, requiring a thorough and complex investigation. Many other granulomatous diseases have the potential to mimic sarcoidosis, whether infectious, occupational, or autoimmune diseases and starting an unnecessary corticosteroid treatment can worsen the patient's prognosis, leading to side effects that can be harder to treat than the actual disease.

Совпадение в полном тексте источника
… Arthritis Rheum. 2007;56:208–214. doi: 10.1002/art.22294. 54. Oshagbemi O.A., Driessen J.H.M., Pieffers A., Wouters E.F.M., Geusens P., Vestergaard P., van den Bergh J., Franssen F.M.E., de Vries F. … Arthritis Rheum. 2022;55:152010. doi: 10.1016/j.semarthrit.2022.152010. 59. Cisneros J.R., Murray K.M. Corticosteroids in tuberculosis. Ann. Pharmacother. 1996;30:1298–1303. doi: 10.1177/106002809603001115. 60. Amin A., Vartanian A., Yegiazaryan A., Al-Kassir A.L., Venketaraman V. …

VEXAS Syndrome-Review.

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined refractory adult-onset autoinflammatory syndrome caused by somatic mutations in the ubiquitin-like modifier-activating enzyme 1 (UBA1) gene in hematopoietic stem and progenitor cells, resulting in a shift in UBA1 isoform expression. Thus, patients develop a spectrum of systemic inflammatory manifestations and hematologic symptoms. To date, patients respond poorly to immune suppressive drugs, except high-dose glucocorticoids, and no treatment guidelines have been established. Given the high mortality ra

Совпадение в полном тексте источника
… syndrome) with prominent supraglottic larynx involvement: a case-based review Clin Rheumatol 2022 41 11 3565 3572 35986821 10.1007/s10067-022-06338-1 23 Tsuchida N Kunishita Y Uchiyama Y Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis Ann Rheum … enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome JAAD Case Rep 2022 23 15 19 35391910 10.1016/j.jdcr.2022.02.022 PMC8980309 67 Kirino Y Takase-Minegishi K Tsuchida N Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan Ann Rheum …

Targeted treatment of autoimmune cytopenias in primary immunodeficiencies.

Primary Immunodeficiencies (PID) are a group of rare congenital disorders of the immune system. Autoimmune cytopenia (AIC) represents the most common autoimmune manifestation in PID patients. Treatment of AIC in PID patients can be really challenging, since they are often chronic, relapsing and refractory to first line therapies, thus requiring a broad variety of alternative therapeutic options. Moreover, immunosuppression should be fine balanced considering the increased susceptibility to infections in these patients. Specific therapeutic guidelines for AIC in PID patients are lacking. Treatm

Совпадение в полном тексте источника
… Ann Rheum Dis (2015) 74:1474–8. doi: 10.1136/annrheumdis-2014-206016 36. Pasquale R, Giannotta JA, Barcellini W, Fattizzo B. Bortezomib in autoimmune hemolytic anemia and beyond. Ther Adv Hematol (2021) 12:20406207211046428. doi: 10.1177/20406207211046428 37. … Ann Rheum Dis (2015) 74(11):2006–15. doi: 10.1136/annrheumdis-2013-205067 49. Montillo M, O’Brien S, Tedeschi A, Byrd JC, Dearden C, Gill D, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. …

Multidisciplinary supportive care in systemic light chain amyloidosis.

The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment has been directed to the underlying plasma cell clone with or without high dose chemotherapy followed by autologous stem cell transplantation using melphalan based conditioning. Now with the approval of highly tolerable anti-CD38 monoclonal antibody daratumumab based anti-plasma cell therapy in 2021, high rates of hematologic complete responses are possible even in patients who are otherwise deemed not a candidat

Совпадение в полном тексте источника
… Arthritis Rheum. 2007;56:3858–68. doi: 10.1002/art.22959. 73. Muchtar E, Derudas D, Mauermann M, et al. Systemic immunoglobulin light chain amyloidosis-associated myopathy: presentation, diagnostic pitfalls, and outcome. Mayo Clin Proc. 2016;91:1354–61. doi: 10.1016/j.mayocp.2016.06.027. 74. … Semin Arthritis Rheum. 2013;43:405–12. doi: 10.1016/j.semarthrit.2013.07.004. …

Hemophagocytic Lymphohistiocytosis

Hemophagocytic lymphohistiocytosis (HLH) is an aggressive life-threatening disease that consists of uncontrolled activated lymphocytes and macrophages that secrete excessive cytokines. Symptoms and laboratory findings of HLH include prolonged fever, cytopenia, hepatosplenomegaly, liver dysfunction, hypertriglyceridemia, hyperferritinemia, increased soluble interleukin-2 receptor, low fibrinogen, and neurological problems. HLH has two forms: primary (familial autosomal recessive) or secondary (related to infections, malignancy, autoimmune and metabolic disorders, transplantations, chimeric anti

Совпадение в полном тексте источника
… Ann Rheum Dis. 2016;75:481–489. doi: 10.1136/annrheumdis-2015-208982. 93. Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. … Arthritis Rheum. 2008;58:2892–2896. doi: 10.1002/art.23734. 94. Fardet L, Lambotte O, Meynard JL, et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. AIDS. 2010;24:1299–1306. doi: 10.1097/QAD.0b013e328339e55b. 95. …

The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.

Chemokines are an indispensable component of our immune system through the regulation of directional migration and activation of leukocytes. CXCL8 is the most potent human neutrophil-attracting chemokine and plays crucial roles in the response to infection and tissue injury. CXCL8 activity inherently depends on interaction with the human CXC chemokine receptors CXCR1 and CXCR2, the atypical chemokine receptor ACKR1, and glycosaminoglycans. Furthermore, (hetero)dimerization and tight regulation of transcription and translation, as well as post-translational modifications further fine-tune the s

An observational descriptive cross sectional multicenter study of health related quality of life among Iraqi patients after total hip replacement.

BackgroundHip replacement is highly effective procedure to decrease pain and disability in patients with hip arthritis and accordingly can affect health related quality of life (HRQOL). Globally, limited studies have reported impact of total hip replacement (THR) on HRQOL and there is no previous reports of HRQOL among Iraqi patients after THR.ObjectiveTo evaluate HRQOL in patients after THR and to assess impact of sociodemographic characteristics on it if present.Patients and methodsA multicenter cross sectional study was conducted on 96 patients with THR in Iraq. Sociodemographic characteris

Совпадение в полном тексте источника
… Arthritis Rheum. 2007;57:1375–1380. doi: 10.1002/art.23101. 11. Havelin L., Fenstad A.M., Salomonsson R. The Nordic Arthroplasty Register Association: a unique collaboration between 3 national hip arthroplaty registries with 280, 201 THRs. …

Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw.

ObjectivesTo identify post-treatment prognostic factors for medication-related osteonecrosis of the jaw (MRONJ).Materials and methodsWe evaluated 54 MRONJ patients who visited the Department of Dentistry, Ajou University Hospital, from May 2007 to March 2014. Twenty-one patients were surgically managed with debridement or sequestrectomy and 33 patients were conservatively managed using antibiotics. Correlations of age, sex, stage, bisphosphonate duration and type, and drug holiday with the prognosis of MRONJ were investigated. Correlations were verified by logistic regression analysis and t-te

Совпадение в полном тексте источника
… J Korean Rheum Assoc. 2006;13:150–154. 10. Carlson ER. Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg. 2014;72:655–657. doi: 10.1016/j.joms.2013.12.007. 11. …

Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Although increased bone formation is a prominent feature of patients with osteosclerotic metastases from prostate cancer, there is also some evidence for increased bone resorption. The aim of this study was to compare the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment. Thirty-nine patients with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic hyperplasia and 355 healthy age-matched men were

Совпадение в полном тексте источника
… Arthritis Rheum. 1998 Feb;41(2):354–360. doi: 10.1002/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5. Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., Delmas P. D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. …

Pathogenesis and kidney prognosis of renal amyloidosis.

Light chain (AL), serum amyloid A (AA), transthyretin (ATTR), leukocyte cell derived chemotaxin 2 (ALECT2), and fibrinogen Aa (AFib) amyloidosis are some of the most common types of protein-deposition disorders involving the kidney. Each amyloidogenic protein differs in its origin and little is known about the exact mechanisms that govern renal tropism and tissue injury for each amyloid subtype. While amyloidogenic precursor protein is different in each subtype of amyloidosis, its aggregation into fibrils depositing in target organs and leading to disruption of tissue architecture and progress

Совпадение в полном тексте источника
… Ann Rheum Dis 62(4):368–369. 10.1136/ard.62.4.368 12634242 10.1136/ard.62.4.368 PMC1754503 79. … Ann Rheum Dis 70(8):1511–1512. 10.1136/ard.2010.143438 21173015 10.1136/ard.2010.143438 81. …

Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment.

Pyoderma gangrenosum (PG) is a rare inflammatory skin disease belonging to the group of neutrophilic dermatoses. The pathogenesis of PG involves a predisposing genetic background that facilitates a dysregulated innate and adaptive immune response, with an imbalance between pro-inflammatory and anti-inflammatory mediators, leading to neutrophil-driven inflammatory damage. Several immunosuppressants and immunomodulatory drugs are currently available for the treatment of PG, in combination with topical therapies, wound management and pain control strategies. Systemic corticosteroids and cyclospor

Совпадение в полном тексте источника
… Mistry P Carmona-Rivera C Ombrello AK Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome Ann Rheum Dis 2018 77 12 1825 1833 10.1136/annrheumdis-2018-213746 30131320 PMC6728908 Mistry P, Carmona-Rivera C, Ombrello AK et al (2018) Dysregulated … Ann Rheum Dis 77(12):1825–1833. 10.1136/annrheumdis-2018-213746 30131320 10.1136/annrheumdis-2018-213746 PMC6728908 46. …

Secondary fracture prevention in primary care: a narrative review.

The global burden of osteoporosis continues to rise with an ageing population. Untreated osteoporotic fractures not only heighten the risk of subsequent fractures but are associated with excess mortality. Although primary care guidelines consistently stress the importance of secondary fracture prevention, fewer than 20% of patients are appropriately treated for osteoporosis following an initial osteoporotic fracture. This worldwide phenomenon is known as the osteoporosis care gap. This literature review examines the barriers to secondary fracture prevention in primary care and evaluates the ef

Совпадение в полном тексте источника
… Osteoporos Int 15(3):175–179 14691617 10.1007/s00198-003-1514-0 23. van Geel TA van Helden S Geusens PP Winkens B Dinant GJ Clinical subsequent fractures cluster in time after first fractures Ann Rheum Dis 2009 68 1 99 102 18677009 10.1136/ard.2008.092775 van Geel TA, van Helden S, Geusens PP, Winkens … Ann Rheum Dis 68(1):99–102 18677009 10.1136/ard.2008.092775 24. …

Проверка и оценка применения Комплекса реабилитации МКФ: польская клиническая перспектива.

Проверка функционального статуса пациента в процессе реабилитации имеет важное значение для постоянного повышения качества предлагаемых реабилитационных услуг. Эта возможность обеспечивается за счет использования Международной классификации функционирования, инвалидности и здоровья (МКФ) и основных наборов МКФ, разработанных на ее основе. Цель этого исследования заключалась в том, чтобы подтвердить и оценить применение Комплекса реабилитации МКФ для реабилитационных пациентов в клинической практике в юго-восточной Польше. В исследовании использовалась польская версия справочника по рейтингам д

Совпадение в полном тексте источника
… Ann Rheum Dis. 2007. 10.1136/ard.2006.058693. 34. Prodinger B, Stucki G, Coenen M, Tennant A. The measurement of functioning using the international classification of functioning. Disability and health: comparing qualifier ratings with existing health status instruments. …

Utility of blood procalcitonin concentration in the management of cancer patients with infections.

Diagnosis of infections in cancer patients is usually problematic since differentiating between infection and fever of unknown origin is often a considerable clinical challenge. In general, increase concentration of blood procalcitonin (PCT) is associated with severe bacterial infection. PCT with an optimal cutoff level of 0.5 ng/mL seems to be the most helpful biochemical parameter in detecting severe infections, mainly bloodstream infection, in patients with hematological cancers. In all clinical situations, the elevated level of PCT should be carefully analyzed, always with a thorough physi

Совпадение в полном тексте источника
… Arthritis Rheum. 2012;64(9):3034–3042. doi: 10.1002/art.34512. 31. Wang C, Zhong D, Liao Q, Kong L, Liu A, Xiao H. Procalcitonin levels in fresh serum and fresh synovial fluid for the differential diagnosis of knee septic arthritis from rheumatoid arthritis, osteoarthritis and gouty arthritis. …

Baby you can drive my CAR-T cells.

ObjectiveTo evaluate the potential of chimeric antigen receptor T-cell (CAR-T) therapy in revolutionizing the treatment of systemic lupus erythematosus (SLE) and to outline necessary future steps for its implementation.MethodsA careful literature search was conducted for relevant English language papers on pubmed.ResultsPreliminary data suggest that CAR-T therapy could significantly improve SLE outcomes. Demonstrating remarkable clinical and serologic improvements in SLE patients, with all treated patients achieving remission and discontinuing conventional steroids and immunosuppressive drugs.

Совпадение в полном тексте источника
… Ann Rheum Dis 2017; 76(12): 2009–2016. 10. Jung J-Y, Suh C-H. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med 2017; 32(3): 429–438. 11. Friedberg E, Wohlfarth P, Schiefer AI, et al. …

Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study.

(1) Background: Calcinosis cutis is a frequent symptom of autoimmune connective tissue diseases leading to pain, transcutaneous expulsion of calcified material and bacterial superinfection. There is a high need for new therapeutic options as no standardized treatment algorithm is established. While case reports indicate beneficial effects of bisphosphonates, standardized evaluation of treatment effects is missing. (2) Methods: In this retrospective analysis we evaluate the effects of intravenous pamidronate, a second-generation bisphosphonate, in seven patients with calcinosis cutis using cons

Совпадение в полном тексте источника
… Arthritis Rheum. 2016;46:344–349. doi: 10.1016/j.semarthrit.2016.05.008. 4. Valenzuela A., Song P., Chung L. Calcinosis in scleroderma. Curr. Opin. Rheumatol. 2018;30:554–561. doi: 10.1097/BOR.0000000000000539. 5. Drake M.T., Clarke B.L., Khosla S. …

The various therapeutic applications of the medical isotope holmium-166: a narrative review.

Over the years, a broad spectrum of applications of the radionuclide holmium-166 as a medical isotope has been established. The isotope holmium-166 is attractive as it emits high-energy beta radiation which can be used for a therapeutic effect and gamma radiation which can be used for nuclear imaging purposes. Furthermore, holmium-165 can be visualized by MRI because of its paramagnetic properties and by CT because of its high density. Since holmium-165 has a natural abundance of 100%, the only by-product is metastable holmium-166 and no costly chemical purification steps are necessary for pro

Совпадение в полном тексте источника
… Arthritis Rheum. 1991;34(12):1521–1530. doi: 10.1002/art.1780341208. Khorami-Moghadam A, Bolouri B, Jalilian AR, Bahrami-Samani NM, Mazidi SM, Alirezapour B. … Arthritis Rheum. 1977;20(7):1334–1342. doi: 10.1002/art.1780200706. Smith SV, et al. [166Dy]dysprosium/[166Ho]holmium in vivo generator. Appl Radiat Isot. 1995;46(8):759–764. doi: 10.1016/0969-8043(94)00149-T. Smits ML, et al. …